Ozempic linked to lower Alzheimer's risk in people with Type 2 diabetes
UC expert comments on study to NBC News
The University of Cincinnati's Alberto Espay, MD, commented to NBC News on new research published Oct. 24 that found semaglutide, the active ingredient in Ozempic and Wegovy, appeared to reduce the risk of Alzheimer’s disease in people with Type 2 diabetes.
The new study compared semaglutide to seven other diabetes drugs, including metformin, insulin and older GLP-1 drugs, including liraglutide.
Researchers found that patients prescribed semaglutide had a significantly lower risk for Alzheimer’s disease than those who had taken one of the seven other diabetes drugs. The results were consistent across gender, age and weight.
Espay, who was not involved in the study, told NBC News more research is needed to determine if the drugs actually work against Alzheimer's. He noted previous early research showed similar positive effects for people who took drugs including statins or insulin, but none of those potential treatments panned out.
“Just as with statins, NSAIDs and insulin, we should be cautious about claiming semaglutide can treat or prevent Alzheimer’s based on this study alone,” Espay said.
Featured photo at top of a semaglutide injection pen. Photo/aprott/iStock.
Related Stories
Forbes: Could music be a game-changer for digital health?
August 27, 2021
UC research examining a music app to help breast cancer survivors is mentioned by Forbes.
WVXU: COVID-19, lung and brain images and stroke risk
March 15, 2021
University of Cincinnati researchers say for the first time they have a visual correlation between the severity of COVID-19 in the lungs and the effect on patients' brains, WVXU-FM reports.
ABC12: New drug kills metastatic melanoma
May 18, 2021
A team of scientists at the University of Cincinnati is developing a therapy that — when taken together — can improve existing melanoma treatments.